{
  "abstract": "We appreciate the comments by Chen et al1 on our recent publication entitled ‘Hepatitis B Surface Antigen Level Identifies Inactive Chronic Hepatitis B Patients from Asia with HCC Risk Below Surveillance Threshold’.2 Their comments highlight the heterogeneity among patients with inactive chronic hepatitis B (CHB) and raise an important clinical question: Should nucleos(t)ide analogue (NA) therapy be initiated in patients with inactive CHB with high hepatitis B surface antigen (HBsAg) levels?",
  "authors": [
    {
      "affiliations": [
        "Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan",
        "Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan",
        "Medical Research, National Taiwan University Hospital, Taipei, Taiwan"
      ],
      "name": "Tai-Chung Tseng"
    },
    {
      "affiliations": [
        "Genomics Research Center, Academia Sinica, Taipei, Taiwan",
        "Institute of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan",
        "Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan",
        "Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan",
        "Doctoral Program of Clinical and Experimental Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan"
      ],
      "name": "Hwai-I Yang"
    },
    {
      "affiliations": [
        "Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan",
        "Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan",
        "Medical Research, National Taiwan University Hospital, Taipei, Taiwan",
        "Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan"
      ],
      "name": "Jia-Horng Kao"
    }
  ],
  "title": "Reply to: ‘Rethinking “inactive chronic hepatitis B”: should we treat patients with high HBsAg levels?’",
  "uid": "e68d31b3-5fc4-5ebb-b1d8-3ea354fdd203"
}